Kelun Wins World’s First TROP2 ADC Approval In Lung Cancer

 
• By Dexter Jie Yan
  
Merck/Kelun and AstraZeneca/Daiichi Sankyo are locked in a race to win lung cancer labels for their TROP2 ADCs. (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from Focus On Asia